Bedaquiline (fumarate)

Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.

Product Specifications

CAS Number

[845533-86-0]

Product Name Alternative

R403323; TMC207 fumarate; R207910 fumarate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Bedaquiline-fumarate.html

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(/C=C/C(O)=O)=O.BrC1=CC=C(N=C(OC)C([C@H]([C@@](C2=CC=CC3=C2C=CC=C3)(O)CCN(C)C)C4=CC=CC=C4)=C5)C5=C1

Molecular Formula

C36H35BrN2O6

Molecular Weight

671.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Jang JC, et al. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. J Microbiol. 2017 Apr 20.|[2]Pang Y, et al. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017 Apr 24;61 (5) .|[3]Chahine EB, et al. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014 Jan;48 (1) :107-15.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

ACS Infect Dis. 2024 Sep 13;10 (9) :3222-3232.|bioRxiv. 2025 July 04.|bioRxiv. 2025 Nov 19:2025.11.19.689313.|Università Vita-Salute San Raffaele. 2022 Apr 08. 34.|ACS Chem Biol. 2022 Jan 21;17 (1) :39-53.|ACS Infect Dis. 2021 Jan 8;7 (1) :141-152.|ACS Infect Dis. 2024 Feb 9;10 (2) :513-526.|ACS Infect Dis. 2025 Apr 11;11 (4) :929-939.|Advanced Biochemistry, University of Madras, American.2019, Jan|Antimicrob Agents Chemother. 2019 Sep 23;63 (10) :e01191-19.|Antimicrob Agents Chemother. 2020 Jan 27;64 (2) :e01540-19.|Antimicrob Agents Chemother. 2020 Mar 24;64 (4) :e02404-19.|Antimicrob Agents Chemother. 2021 Aug 17;65 (9) :e0095621.|Antimicrob Agents Chemother. 2021 Mar 18;65 (4) :e01445-20.|Antimicrob Agents Chemother. 2023 Feb 16;67 (2) :e0145922.|Antimicrob Agents Chemother. 2024 Oct 29:e0094524.|Antimicrob Agents Chemother. 2024 Oct 29:e0105124.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Antimicrob Agents Chemother. 2025 May 27:e0184724.|Antimicrob Agents Chemother. 2025 Sep 11:e0079525.|Authorea. 2025 Sep 17.|bioRxiv. 2024 Oct 30:2024.10.30.620736.|bioRxiv. 2025 February 06.|bioRxiv. 2025 Oct 17.|Cell. 2023 May 11;186 (10) :2176-2192.e22.|Commun Biol. 2025 Feb 6;8 (1) :187.|Commun Biol. 2025 Oct 6;8 (1) :1425.|Dis Model Mech. 2021 Dec 1;14 (12) :dmm049145.|Eur J Med Chem. 2022 Nov 15:242:114639.|Front Cell Infect Microbiol. 2016 Nov 8:6:145.|Front Microbiol. 2018 Aug 15:9:1898.|Front Microbiol. 2021 Feb 25;12:647611.|Int J Pharm. 2024 Mar 25:653:123920.|J Biol Chem. 2024 Feb;300 (2) :105618.|J Clin Microbiol. 2025 Aug 20:e0084125.|J Pharm Biomed Anal. 2023 Oct 25:235:115658.|mBio. 2021 Jun 29;12 (3) :e0108821.|Microbiol Spectr. 2021 Sep 3;9 (1) :e0004521.|Microbiol Spectr. 2023 Dec 12;11 (6) :e0228223.|mLife. 2025 Apr 15;4 (2) :155-168.|Nanomedicine. 2025 Apr;20 (8) :777-789.|Nat Commun. 2021 Jun 21;12 (1) :3816.|Nat Commun. 2025 May 10;16 (1) :4366.|Pharmaceuticals (Basel) . 2023 Sep 15;16 (9) :1309.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2023 May 2.|SLAS Discov. 2020 Sep;25 (8) :895-905.|University of Manitoba. Department of Medical Microbiology and Infectious Diseases. 2022 Jan.|Vet Res. 2023 Dec 19;54 (1) :123.|Zoonoses. 2023 Feb 2.